Two ongoing trials investigating ribociclib and one investigating abemaciclib as selective inhibitors of CDK4 and CDK6 are investigating the role of CDK inhibitors in treating meningiomas (NCT02933736, NCT03220646, NCT02523014). This evidence concerns the gene CDK4 and meningioma.